Abstract
Severely ill patients in intensive care units (ICU) are frequently at risk of developing fungal infections. Itraconazole (ITCZ), a triazole antifungal agent, is used for the treatment of aspergillosis, candidiasis, and cryptoccosis. The present retrospective pharmacokinetic–pharmacodynamic (PK–PD) analysis was designed to find any factors affecting clinical outcome of ITCZ treatment, and was performed to evaluate the appropriateness of the current dosage regimen in ICU patients. All of the patients admitted to Aichi Medical University Hospital ICU in 2008 who were treated with ITCZ injections for fungal infections were included in the study. After outcomes had been classified as cure or failure, a PK–PD analysis was performed. In addition, the probability of PD target attainment was assessed using a Monte Carlo simulation. Ten patients were enrolled in the study. Satisfactory outcomes were obtained in 4 of the 10 patients. No significant differences in the area under the 24-h curve (AUC0–24), peak concentrations and trough concentrations were observed between the two groups. However, it was observed that the higher the AUC0–24, the better the outcome. Moreover, our results showed that additional dosage is needed to attain a sufficiently high AUC0–24/MIC in about 20% of patients. Our retrospective study is the first to show that it is important to consider the host’s condition when ITCZ is administered, especially in ICU patients. The present findings are also useful for optimizing the individual dosage of ITCZ based on AUC0–4 for the treatment of patients infected with Candida spp.
Similar content being viewed by others
References
Link H, Bohme A, Cornely OA, Höffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm M, Auner HW. Antimicrobial therapy of unexplained fever in neutropenic patients—guidelines of the Infectious Disease Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG—German Cancer Society). Ann Hematol. 2003;82(Suppl 2):S105–17.
Klastersky J. Empirical antifungal therapy. Int J Antimicrob Agents. 2004;23:105–12.
Jun HX, Zhixiang S, Chun W, Reksodiputro AH, Ranuhardy D, Tamura K, Matsumoto T, Lee DG, Purushotaman SV, Lim V, Ahmed A, Hussain Y, Chua M, Ong A, Liu CY, Hsueh PR, Lin SF, Liu YC, Suwangool P, Jootar S, Picazo JJ. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents. 2005;26(Suppl 2):S128–32.
Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother. 2005;56(Suppl 1):i33–8.
Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161–89.
Eggimann P, Garbino J, Pittet D. Management of Candida sepsis infections in critically ill patients. Lancet Infect Dis. 2003;3:772–85.
Vincent JL, Anaissie E, Bruining H, Demajo W, el-Ebiary M, Haber J, Hiramatsu Y, Nitenberg G, Nystrom PO, Pittet D, Rogers T, Sandven P, Sganga G, Schaller MD, Solomkin J. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med. 1998;24:206–16.
Buchner T, Fegeler W, Bernhardt H, Brockmeyer N, Duswald KH, Herrmann M, Heuser D, Jehn U, Just-Nubling G, Karthaus M, Maschmeyer G, Müller FM, Müller J, Ritter J, Roos N, Ruhnke M, Schmalreck A, Schwarze R, Schwesinger G, Silling G. Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators. Eur J Clin Microbiol Infect Dis. 2002;21:337–52.
Dimopoulos G, Karabinis A, Samonis G, Falagas ME. Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. Eur J Clin Microb Infect Dis. 2007;26:377–84.
Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med. 1989;149:2349–53.
Blumberg HM, Jarvis WR, Soucie JM, Edwars JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP. Risk factors for Candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33:177–86.
Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microb Rev. 2007;20:133–63.
Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250–60.
Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–66.
Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis. 2004;39(Suppl 1):S38–43.
Hostetler JS, Heykants J, Clemons KV, Woestenborghs R, Hanson LH, Stevens DA. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother. 1993;37:2224–7.
Odds FC, Bossche HV. Antifungal activity of itraconazole compared with hydroxyl-itraconazole in vitro. J Antimicrob Chemother. 2000;45:371–3.
Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T, Marklein G, Schmidt-Wolf IG. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999;42:443–51.
Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses. 1999;42:591–600.
David A. In vivo pharmacodynamics of antifungal drugs in treatment of Candidiasis. Antimicrob Agents Chemother. 2003;47:1179–86.
Burggess DS, Hastings RW. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time–kill methodology. Diagn Microbil Infect Dis. 2000;38:87–93.
Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother. 1998;42:3018–21.
Schafer-Korting M, Korting HC, Amann F, Peuser R, Lukacs A. Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study. Antimicrob Agents Chemother. 1991;35:2053–6.
Schafer-Korting M, Korting HC, Ritter W, Obermuller W. Influence of serum protein binding on the in vitro activity of antifungal agents. Infection. 1995;23:292–7.
Zhanel GG, Saunders DG, Hoban DJ, Karlowsky JA. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob Agents Chemother. 2001;45:2018–22.
Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47:3165–9.
Andes D, van Ogtrop KM. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother. 1999;43:2116–20.
Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K. Intravenous and oral itraconazole versus intravenous amphotericin B dexycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135:412–22.
Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother. 2005;56(Suppl 1):i17–22.
Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, Cauwenbergh G. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32(Suppl 1):67–87.
Okuda T, Watanabe N, Okuda A, Takao M, Takayanagi K. Monitoring the plasma level of itraconazole administration for prevention of fungal infection: the relationship between the plasma itraconazole level and several clinical parameters. Jpn J TDM. 2008;25:8–12.
Acknowledgments
We thank the clinicians and pharmacists that have assisted with the provision of data for this project.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hagihara, M., Kasai, H., Umemura, T. et al. Pharmacokinetic–pharmacodynamic study of itraconazole in patients with fungal infections in intensive care units. J Infect Chemother 17, 224–230 (2011). https://doi.org/10.1007/s10156-010-0102-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10156-010-0102-4